Skip to main content

Emotra joins BioVentureHub

By Jamie Smith - 6 Feb 2020
Emotra, a medical device company with a proprietary method to identify an at-risk group in depression, is moving into AstraZeneca’s BioVentureHub in Gothenburg.

Emotra has developed EDOR-Test, a diagnostic method to help identify patients with an increased risk of relapsing into depression. EDOR-Test is a psychophysiological test to identify patients that are hyporeactive, i.e. having or showing abnormally fast habituation to stimuli.

Daniel Poté, President and CEO of Emotra, says, “Being part of the BioVentureHub’s collaborative culture, and having access to world-class life science facilities and expertise, will help us develop our research in depression relapse, and other risks associated with hyperactivity. This supports our goal to support physicians with more complete information to develop more individualized treatment plans to help patients.”

Magnus Björsne, CEO of AstraZeneca BioVentureHub, says, “We are working to create an innovative 4D life science environment in the BioVentureHub where we blend drug, device, diagnostic and digital health companies. So we’re excited to have Emotra, another diagnostic company, join us. By being here, we hope Daniel and his team will get new opportunities to collaborate, innovate and develop their research and methods in this important area of healthcare.”

About Emotra
Emotra AB (publ) is a medical technology company that carries out research, development, clinical studies and marketing in the area of mental health. The company’s product, EDOR®-Test, is a proprietary and objective psychophysiological test for detecting if patients suffering from depression are hyporeactive. Please visit www.emotra.se

About AstraZeneca BioVentureHub
AstraZeneca started the BioVentureHub in 2014 as an open ecosystem for innovation and to strengthen the competitiveness of and dynamics in the life science industry. Based on an innovative public-private-partnership model, the BioVentureHub offers small and medium-sized companies and academic groups from Sweden and abroad a unique opportunity to co-locate with and tap into the power of AstraZeneca's world-class researchers and facilities, and to work closely with each other. There are currently 29 small and medium-sized companies, as well as 1 academic group, in the BioVentureHub. Please visit www.azbioventurehub.com

For more information, please contact:
Daniel Poté, Emotra
Tel. +46 (0)732-34 41 93, E-mail: daniel@emotra.se

Jamie Smith, AstraZeneca BioVentureHub
Tel. +46 (0)723-75 75 07, E-mail: jamie.smith1@astrazeneca.com